Drugs Made In America Acquisition Corp. Ordinary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMAA research report →
Price Chart
About the company
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses.
- CEO
- Roger Bendelac
- IPO
- 2025
- Employees
- 2
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DMAA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $260.37M
- P/E
- 54.64
- PEG
- -0.55
- P/S
- 0.00
- P/B
- -29.10
- EV/EBITDA
- -98.86
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3.53%
- ROIC
- -1.83%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-2,816,013
- Net Income
- $5.94M+1240317.7%
- EPS
- $0.19+439.3%
- OCF Growth
- -182675.3%
- FCF Growth
- -182675.3%
- 52W High
- $10.73
- 52W Low
- $10.22
- 50D MA
- $10.67
- 200D MA
- $10.51
- Beta
- 0.00
- RSI (14)
- 79
- Avg Volume
- 35.54K
No earnings-call transcripts are available for DMAA yet.
- Free Float
- 76.5%
- Shares Outstanding
- 24.28M
- Float Shares
- 18.56M
of shares held by institutions
39 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mizuho Securities Usa LLC | 542.96K | ▲ 542.96K |
| Atw Spac Management LLC | 500.00K | ▼ 70.00K |
| Clear Street LLC | 112.61K | ▲ 112.61K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 25 | Drugs Made In America Acquisition LLC | buy | 30,000 |
| Feb 18, 25 | Drugs Made In America Acquisition LLC | buy | 30,000 |
| Feb 18, 25 | Stockwell Lynn | buy | 30,000 |
| Feb 18, 25 | Stockwell Lynn | buy | 30,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | buy | 400,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | other | 400,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | sell | 5,698,363 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | buy | 400,000 |
| Jan 29, 25 | Stockwell Lynn | other | 400,000 |
| Jan 29, 25 | Stockwell Lynn | sell | 5,698,363 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DMAA coverage
Recent articles, reports, and earnings notes.
No research on DMAA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMAA report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.